Adaptive Biotechnologies (ADPT) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $25.80 --0%
EPS Growth %: -250.0%
Financial Fact:
Diluted (in Shares): -23.01M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -250.0%
Financial Fact:
Diluted (in Shares): -23.01M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.25), $0.11 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.55 million versus the consensus estimate of $65.75 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- ADP Employment Change (Oct) 86K vs 67K Expected
- SmartRent (SMRT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
